 Connection
Maryam Asgari to United States Food and Drug Administration
This is a "connection" page, showing publications Maryam Asgari has written about United States Food and Drug Administration.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.338 |
|
|
|
-
Karas L, Lu CY, Agrawal PB, Asgari MM. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers. J Am Acad Dermatol. 2019 09; 81(3):867-877.
Score: 0.156
-
Albrecht J, Adamson AS, Barbieri JS, Bennett DD, Kiracofe EA, Kourosh AS, Leslie KS, Merola JF, Nguyen J, Siegfried E, Strickland N, Olbricht S, Asgari MM. Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment. J Am Acad Dermatol. 2019 02; 80(2):577-578.
Score: 0.150
-
Albrecht J, Lebwohl M, Asgari MM, Bennett DD, Cook A, Evans CC, Green LJ, Hodge JA, Kourosh AS, Maloney ME, Howard LM, Olsen EA, Rosenberg SP, Rubin A, Stough DB, Taylor SC, Brod BA. The state and consequences of dermatology drug prices in the United States. J Am Acad Dermatol. 2016 Sep; 75(3):603-605.
Score: 0.032
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|